New immune therapy shows promise for Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase trial tests a new drug called RPTR-1-201 in 150 adults with advanced solid tumors that cannot be cured with standard treatments. The drug works by helping the body's immune cells attack cancer. The study aims to find the safest dose and see if the drug shrinks tu…
Phase: PHASE1, PHASE2 • Sponsor: Repertoire Immune Medicines • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC